This is Part 1 of Navigating the Immunotherapy Landscape in Advanced/Recurrent Endometrial Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.

 

In this video, Drs. Krishnansu Tewari, Noelle Cloven, and Alyssa Bujnak discuss the management of advanced and recurrent endometrial cancer in the context of immunotherapy. The patient is a 58-year-old woman who presents with 6 months postmenopausal vaginal bleeding and mild, diffuse abdominal discomfort and constipation. She has a history of well-controlled hypertension and non–insulin-dependent diabetes, and a family history of colorectal cancer. Following robotic surgery with sentinel lymph node mapping, she is ultimately diagnosed with a stage IIIC1 grade 2 mismatch repair–deficient (dMMR) endometrioid adenocarcinoma

 

The faculty explore how molecular profiling informs adjuvant treatment decisions and how to apply evolving clinical trial data, FDA labeling, and guidelines to patients without measurable disease. They also address the challenges of managing recurrent disease after front-line immunotherapy, including the potential role of clinical trials and novel antibody-drug conjugates.